Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review |
| Συγγραφείς: |
Allel, K. (Kasim), Hernández-Leal, M.J. (María José), Naylor, N.R. (Nichola R.), Undurraga, E.A. (Eduardo A.), Abou-Jaoude, G.J. (Gerard Joseph), Bhandari, P. (Priyanka), Flanagan, E. (Ellen), Haghparast-Bidgoli, H. (Hassan), Pouwels, K.B. (Koen B.), Yakob, L. (Laith) |
| Έτος έκδοσης: |
2024 |
| Συλλογή: |
dadun - Depósito Académico Digital Universidad de Navarra |
| Θεματικοί όροι: |
Área Economía |
| Περιγραφή: |
Introduction: Limited information on costs and the cost-effectiveness of hospital interventions to reduce antibiotic resistance (ABR) hinder efficient resource allocation. Methods: We conducted a systematic literature review for studies evaluating the costs and cost-effectiveness of pharmaceutical and non-pharmaceutical interventions aimed at reducing, monitoring and controlling ABR in patients. Articles published until 12 December 2023 were explored using EconLit, EMBASE and PubMed. We focused on critical or high-priority bacteria, as defined by the WHO, and intervention costs and incremental cost-effectiveness ratio (ICER). Following Preferred Reporting Items for Systematic review and Meta-Analysis guidelines, we extracted unit costs, ICERs and essential study information including country, intervention, bacteria-drug combination, discount rates, type of model and outcomes. Costs were reported in 2022 US dollars ($), adopting the healthcare system perspective. Country willingness-to-pay (WTP) thresholds from Woods et al 2016 guided cost-effectiveness assessments. We assessed the studies reporting checklist using Drummond¿s method. Results: Among 20.958 articles, 59 (32 pharmaceutical and 27 non-pharmaceutical interventions) met the inclusion criteria. Non-pharmaceutical interventions, such as hygiene measures, had unit costs as low as $1 per patient, contrasting with generally higher pharmaceutical intervention costs. Several studies found that linezolid-based treatments for methicillin-resistant Staphylococcus aureus were cost-effective compared with vancomycin (ICER up to $21¿488 per treatment success, all 16 studies¿ ICERs
|
| Τύπος εγγράφου: |
review |
| Περιγραφή αρχείου: |
application/pdf |
| Γλώσσα: |
English |
| Relation: |
https://gh.bmj.com/content/9/2/e013205.abstract; https://hdl.handle.net/10171/69982 |
| Διαθεσιμότητα: |
https://hdl.handle.net/10171/69982 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Αριθμός Καταχώρησης: |
edsbas.14CB7CE |
| Βάση Δεδομένων: |
BASE |